Journal Article

IV.7.1 <i>Pneumocystis carinii</i> pneumonia

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 17, issue suppl_4, pages 36-39
Published in print April 2002 | ISSN: 0931-0509
Published online April 2002 | e-ISSN: 1460-2385 | DOI:
IV.7.1 Pneumocystis carinii pneumonia

Show Summary Details



A. Approximately 5% of patients develop Pneumocystis carinii pneumonia (PCP) after renal transplantation if they do not receive prophylaxis. PCP is a severe disease, with a very high fatality rate. Therefore, all renal transplant recipients should receive PCP prophylaxis. The treatment of choice is trimethoprim–sulfamethoxazole (TMP–SMX), at a dose of 80/400 mg/day or 160/800 mg every other day, for at least 4 months. Patients who are treated for rejection should receive TMP–SMX prophylaxis for 3–4 months.

(Evidence level A)

B. In the case of TMP–SMX intolerance, aerosolized pentamidine (300 mg once or twice per month) is an alternative for prophylaxis.

(Evidence level A)

C. The first‐line treatment of PCP is high‐dose TMP–SMX. Patients with a PaO2 of <70 mmHg initially should be treated parenterally, and the administration of additional steroids should be considered.

(Evidence level A)

Journal Article.  0 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.